Posters

Clinical outcomes of implantation of posterior chamber phakic intraocular lens with CentraFLOW technology (Hole ICL) for moderate to high myopia

Poster Details

First Author: J.Zhou CHINA

Co Author(s):                        

Abstract Details

Purpose:

Aim To assess the safety, efficacy, predictability and stability of implantation of Visian ICL with CentraFLOW technology for correction myopia.

Setting:

Chengdu Aier eye hospital, China.

Methods:

This study evaluated 79 eyes of 40 patients who underwent Hole ICL implantation with spherical equivalents of -10.17±3.67D. The uncorrected (UDVA) and corrected (CDVA)distance visual acuities, refractive error , intraocular pressure, endothelial cell count,central vault, and adverse events of the surgery were recorded before and up to 3 month after surgery.

Results:

At 3 months postoperatively, the mean spherical equivalent decreased to -0.07±0.29D，93.6% of eyes were within ±0.5D and 100% eyes were within ±1.00D of targeted correction. The mean UCVA and CDVA were 20/20 or better in 96.2% and100 % of eyes respectively. The safety and efficacy indices 1.35±0.23 and 1.22±0.28 respectively . No significant rise in intraocular pressure(including pupillary block) or secondary cataract occurred in any case during the period of observation. At 3 months the mean vault was 410.55±169.47um (range190 to 680 um) and the endothelial cell loss was 2.9%.

Conclusions:

Implantation of Hole ICL offered good results for all measures of safety,efficacy predictability and stability for the correction of high myopia, even without peripheral iridotomy or iridectomy.

Financial Disclosure:

NONE